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Parasitic and infectious diseases cause over 9.5 million deaths worldwide annually, yet only 3 of the over 50 
approved antibodies are for infectious conditions. This disparity can be attributed to the high costs of antibody 
development in the face of small molecule alternatives and effective vaccines; however, a growing niche of 
specialty applications and the emergence of antibioticresistant strains make antibody therapeutics a likely 
eventuality. Particular challenges for developing therapeutic proteins for pathogenic diseases are that high 
variability in circulating strains, mutability within the host, and immune escape mechanisms limits the efficacy of 
monoclonal antibody formats. Instead, next generation formats that can exhibit broader activity or induce novel 
immune mechanisms may be a viable approach.   
  
T-cell receptors (TCRs) are membrane-bound molecules that bind peptide-MHC (pMHC) molecules displayed 
by host cells, and are experts at recognizing infected cells. We have replaced one arm of a bispecific antibody 
with a soluble TCR to make a novel TCR/Ig hybrid. To do this, we first developed a system which can display 
TCRs on the surface of CHO cells. After optimization of the TCR format, in particular constant region 
modifications, we replaced the transmembrane region of the construct with an IgG1 hinge and Fc to express 
and purify soluble fusions. By including a knob or hole mutation in the Fc region, we were able to make 
bispecific molecules. Our current format couples an anti-CD3 antibody specificity to a human TCR that is 
associated with cytomegalovirus (CMV). We hypothesize that this format may have unique ability to suppress 
CMV reactivation or infection in transplant recipients or pregnant women.   Ongoing work includes affinity 
maturation of the TCR, as well as testing the bispecific in a cellular model of CMV.   
 
